Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
| Autor: | R. Hull, Tamas Hickish, N Shankley, Gordon D Murray, David Cunningham, Ian Chau, T. R. Kurzawinski, B Theis, J. Black, Phillip Harrison, Chris Russell, Angela Gillbanks, P J Ross, B Kalindjian, Gary Middleton, F Daniels, Mark J. Walker, Peter Harper, J. Prendeville, A. R. Norman |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Time Factors Pancreatic disease medicine.drug_class pancreatic cancer Antineoplastic Agents Pilot Projects Placebo Gastroenterology Antimetabolite fluorouracil law.invention Placebos Double-Blind Method Randomized controlled trial Predictive Value of Tests law Internal medicine Pancreatic cancer Clinical Studies gastrin medicine Humans Single-Blind Method Infusions Intravenous Survival rate Aged Aged 80 and over Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Receptor Cholecystokinin B Surgery Pancreatic Neoplasms Survival Rate Log-rank test Treatment Outcome Oncology Fluorouracil Disease Progression placebo Female business Follow-Up Studies medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6603058 |
| Popis: | Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess the effect of gastrazole in advanced pancreatic cancer. Patients with biopsy-proven, inoperable pancreatic carcinoma were recruited. Trial A compared protracted venous infusion (PVI) gastrazole with PVI placebo, whereas trial B compared PVI gastrazole with PVI fluorouracil (5-FU). Eighteen patients were randomised in trial A. Gastrazole produced significantly better survival compared to placebo (median 7.9 months vs 4.5 months; 1-year survival: 33 vs 11%, respectively; log rank P=0.02). No difference in toxicity was seen between gastrazole and placebo, except central venous catheter and pump complications. Ninety-eight patients were randomised in trial B. No significant survival difference was detected between gastrazole and 5-FU (median: 3.6 vs 4.2 months; 1-year survival: 13.2 vs 26.2%, respectively; log rank P=0.42). Toxicity of gastrazole was mild with significantly less diarrhoea (P=0.03), stomatitis (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|